Cancer Research | The Extracellular Matrix in Oncology

Watch and learn how collagens and tumor fibrosis deactivate the immune system and block access to the tumor leading to poor prognosis and immunotherapy resistance.
This presentation was presented by Nicholas Willumsen, PhD, at the ECM Symposium 2021 organized by Nordic Bioscience.
Nicholas Willumsen joined Nordic Bioscience in 2012 and assumed the position as scientific lead and head of department in Oncology in 2016. His research group focuses on the development of blood-based biomarkers to quantify the tumor stromal reactivity and extracellular matrix biology in cancer patients - a phenomenon that is highly associated with efficacy/resistance to anti-tumor modalities. These novel non-invasive biomarkers to quantify tumor fibrosis and T-cell activity in the tumor microenvironment have clear applicability for immuno-oncology clinical cancer research and are impacting clinical development paradigms. Research activities span from the discovery of novel biomarker targets to investigations in the pre-clinical setting and with translation and validation in phase 1-3 clinical trials.
Nicholas has published more than 40 publications in peer-reviewed journals and has an H-factor of 15. Nicholas Willumsen has supervised 5 PhD students and several MSc students.
For more information, please visit our website: www.nordicbioscience.com/ther...
Or contact us: www.nordicbioscience.com/contact
***
Nordic Bioscience is the leading expert in extracellular matrix (ECM) research with 25+ years of experience in biomarker development, pre-clinical and clinical research. With more than 550 peer-reviewed publications, our science-driven approach has been the evolving force behind our decades of success.
Through our Protein Fingerprint technology, we identify fragments of the ECM that are released from affected tissues and develop blood-based biomarker assays to quantify disease activity with the aim of precision medicine.
By quantifying tissue remodeling, our biomarkers provide true prognostic and predictive value, as we can select the patients who are most likely to respond to a given treatment and thereby function as surrogate biomarkers for clinical trials. Our biomarker assays not only enable faster drug development but also improve disease outcomes for chronically ill patients by predicting treatment response.
Nordic Bioscience is headquartered in Herlev, Denmark, with a high-quality standard laboratory, running clinical trials under Good Clinical Laboratory Practice (GCLP) with accreditation by the College of American Pathologists (CAP) and ISO9001 certificate. Everything in our laboratory supports compliance to FDA 21 CFR Part 11. We employ more than 180 people who are dedicated to improving patient management for a broad range of therapeutic areas including Hepatology, Rheumatology, Dermatology, Oncology, Gastroenterology, Respiratory, Neurodegenerative and Cardiovascular diseases.
Follow us on our other social media channels to stay informed on the latest news of cutting-edge biomarker research!
LinkedIn: / nordicbioscience
Twitter: / nordic_bio
#nordicbioscience #lifescience #tumor #cancer #oncology #fibrosis #tumorfibrosis #biomarkers #proteinfingerprint #webinar #extracellularmatrix #ecm

[@4hero70]

Amazing presentation...full of innovative information that offers chances for new holistic protocols

[@NordicBioscienceAS]

We are glad you enjoyed it! At Nordic, we are working hard to provide insights into all chronic diseases, including insights into tumor fibrosis.